Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.44 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 2/20 | 0.41 |
| ▸ | RARG | P13631 | 2/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2666934 | 0.93 | NOX1 (0.44) | GCKNOX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL5221627 | 0.92 | NOX1 (0.45) | GCKNOX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL2654604 | 0.89 | GCK (0.51) | GCKNOX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL5218374 | 0.86 | PTGER1 (0.45) | NOX1ALDH1A1MAPK1SMN1; SMN2HTT | |
| SCHEMBL5221067 | 0.81 | GCK (0.51) | GCKNOX1ALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL5226263 | 0.80 | NOX1 (0.42) | NOX1ALDH1A1MAPK1HTTTP53 | |
| SCHEMBL2655319 | 0.80 | GCK (0.67) | GCKNOX1RARARARBRARG | |
| SCHEMBL5451958 | 0.76 | GCK (0.65) | GCKRARARARBRARG | |
| SCHEMBL5217769 | 0.73 | GCK (0.55) | GCKNOX1RARARARBRARG | |
| SCHEMBL2653534 | 0.72 | GCK (0.58) | GCKRARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578745-B1 | BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | EP | claimed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | claimed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | claimed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | claimed |
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-7709505-B2 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| EP-1578745-B1 | BENZOFURAN DERIVATivES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2007-11-14 | — | — | EP | disclosed |
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1578745-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | Astrazeneca AB (SE) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004046139-A1 | BENZOFURAN DERIVATES, PROCESS FOR THEIR PREPARATION AND INTERMEDIATES THEREOF | ASTRAZENECA AB (SE) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058353-A1 | Benzofuran derivatives, process for their preparation and intermediates thereof | GCK, PDK2, GCKR | GCK 1/4885NOX1 1042/4885ALDH1A1 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.